Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma

This study investigated cetuximab added to definitive concurrent chemoradiation for esophageal squamous cell carcinoma (ESCC). Previously untreated patients with stage II–IVa ESCC received cetuximab (400 mg/m(2) per week in week 1, then 250 mg/m(2) per week during weeks 2–8), paclitaxel (45 mg/m(2)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Chen, Yongshun, Wu, Xiaoyuan, Bu, Shanshan, He, Chunyu, Wang, Wen, Liu, Jinsong, Guo, Wei, Tan, Bo, Wang, Yanxia, Wang, Jianhua
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2012
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5439109/
https://ncbi.nlm.nih.gov/pubmed/22845557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02393.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia